Proximal Ventures Raises $27.5 Million Debut Fund to Invest in AI-Driven Drug Development Services
Proximal Ventures, a new venture capital firm founded by Sahir Raoof, has successfully raised a $27.5 million debut fund. The firm aims to capitalize on the shift toward artificial intelligence within the pharmaceutical services sector, targeting startups that automate traditionally manual processes such as molecular synthesis, manufacturing scale-up, and clinical trial data analysis. The fund will focus on pre-seed and seed-stage investments, with individual checks ranging from $500,000 to $1.5 million. Proximal Ventures has already deployed capital into six startups, including ChronicleBio. The firm's strategy leverages Raoof’s background in healthcare business development to help early-stage companies navigate the complex commercial landscape of life sciences.
Tickers: $RHHBY
Topics: Artificial Intelligence Drug Development Life Sciences Venture Capital Fundraising